Tehrani v. Hamilton Technologies (No. 23-575) — Supreme Court Petition Denied
Fleur Tehrani sought U.S. Supreme Court review of a lower-tribunal ruling that invalidated US7802571B2, a patent covering a method and apparatus for controlling a ventilator. The petition was denied in just 96 days, leaving the unpatentability finding intact and the patent permanently cancelled.
Supreme Court declines to revive invalidated ventilator control patent
On 16 November 2023, Fleur Tehrani filed Petition No. 23-575 with the U.S. Supreme Court, seeking certiorari review of an invalidity or cancellation determination against US7802571B2 — a patent protecting a method and apparatus for controlling a ventilator. The respondent, Hamilton Technologies, LLC, was represented by Buchanan, Ingersoll & Rooney PC, while Tehrani was represented by Kendrick Intellectual Property Law. The dispute arose in the context of a patentability challenge, with the lower tribunal having found the claims of US7802571B2 unpatentable.
The Supreme Court denied the petition on 20 February 2024, bringing the case to a close after just 96 days. A denial of certiorari carries no precedential weight on the merits, but its practical consequence is decisive: the unpatentability finding from the prior proceeding stands, and US7802571B2 is cancelled. Tehrani cannot continue to enforce the patent against Hamilton Technologies or any third party, and the claims as issued are extinguished.
The 96-day resolution from filing to denial is consistent with the Supreme Court’s standard practice of issuing certiorari denials without extended briefing when it declines to take a case. The public record does not reveal which lower tribunal issued the unpatentability determination, nor the specific grounds — such as anticipation or obviousness — on which the claims were cancelled. What drove the petition and whether any continuation or divisional applications survive is not apparent from the docket.
Filing to settlement in 96 days
96 days — resolved faster than most Supreme Court petition cycles
What the Supreme Court’s denial means for US7802571B2
Certiorari denied — what that actually means
A denial of certiorari is not a ruling on the merits. The Supreme Court declines to hear the vast majority of petitions — typically over 97% — without explaining why. It does not signal agreement with the lower tribunal’s reasoning. However, the practical effect is identical to an affirmance: the unpatentability finding stands and US7802571B2 remains cancelled.
No merits ruling — cancellation upheldUS7802571B2 is cancelled — enforcement is foreclosed
With the petition denied and the unpatentability determination left undisturbed, US7802571B2 can no longer be asserted in litigation. The claims are void. Any pending licensing negotiations relying on this patent lose their leverage, and any prior licensees may have grounds to dispute past royalty obligations. Competitors in the ventilator control space face reduced IP barrier from this specific patent.
Patent extinguishedGrounds for cancellation not specified in the public record
The docket records the basis of termination as ‘Unpatentable’ but does not disclose whether the claims fell on anticipation, obviousness, written description, or another ground. The originating tribunal — likely the Patent Trial and Appeal Board or a similar administrative body — would hold that reasoning. Understanding the specific invalidity theory is critical for assessing whether related patents in Tehrani’s portfolio face similar exposure.
Grounds unknown from public recordRelated applications and continuations may still be at risk
A cancellation of a parent patent does not automatically extinguish continuation, divisional, or continuation-in-part applications sharing similar claim scope. If Tehrani holds related applications, those claims may face inter partes review or ex parte scrutiny using the same prior art that invalidated US7802571B2. Competitors and defendants monitoring this portfolio should search for related application numbers under the original filing US10/935446.
Monitor continuation filingsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Fleur Tehrani | Company | Patent holder asserting US7802571B2 — ventilator control method and apparatusSearch in Eureka ↗ |
| Defendant | Hamilton Technologies, LLC | Company | Hamilton Technologies, LLC — respondent challenging validity of ventilator patentSearch in Eureka ↗ |
| Plaintiff counsel | Mark Robert Kendrick | Attorney | Counsel for Fleur TehraniSearch in Eureka ↗ |
| Defendant counsel | Patrick Christopher Keane | Attorney | Counsel for Hamilton Technologies, LLCSearch in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | U.S. Supreme Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The Supreme Court’s order reads simply ‘Petition DENIED,’ which is the standard form for a certiorari denial and carries no explanatory reasoning. This phrasing does not constitute a ruling on the merits of patentability. For Tehrani, it forecloses all further federal judicial review, leaving the cancellation final. For Hamilton Technologies, it provides certainty that US7802571B2 cannot be revived against them or any future product in the ventilator control space.
US7802571B2 — Method and apparatus for controlling a ventilator
US7802571B2, filed under application number US10/935446, protects a method and apparatus for controlling a ventilator — a critical category of medical device technology used in respiratory support and intensive care. The patent covers control logic or parameter-based approaches to ventilator operation, a domain that sits at the intersection of medical device engineering and software-implemented method claims. Such patents are subject to validity challenges on multiple grounds, including prior art anticipation, obviousness over earlier ventilator control techniques, and potentially subject-matter eligibility under 35 U.S.C. § 101.
Ventilator control technology became a heightened area of IP focus following increased global demand for respiratory devices. Patents in this space are strategically valuable for both medical device manufacturers and individual inventors seeking licensing revenue. The cancellation of US7802571B2 removes one competitive IP barrier in this domain and may embolden further validity challenges against related patents. For companies such as Hamilton Technologies and its competitors, this outcome suggests that aggressively contesting ventilator-related patents through post-grant proceedings can be commercially effective.
Should your team run an FTO against US7802571B2?
US7802571B2 has been cancelled and is no longer enforceable, so it does not itself pose a current infringement risk. However, R&D teams developing ventilator control systems, respiratory monitoring apparatus, or related medical device software should still review the patent’s claim language. Related applications, continuations, or patents with overlapping claim scope filed by the same inventor may remain active, and the cancelled claims define the technical territory the inventor sought to protect.
PatSnap Eureka’s FTO Search Agent allows product teams to map all patents related to ventilator control methods — including continuation families, co-assigned patents, and patents citing US7802571B2 as prior art. Running a claim-level analysis against your product’s feature set will surface any surviving related rights that could present residual risk. Setting up claim monitoring on the US10/935446 family ensures you are alerted if any continuation is asserted in the future.
Run a freedom-to-operate analysis on US7802571B2 to assess your product’s exposure
Run FTO in Eureka →Similar Supreme Court patent petition denials in medical device IP
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the medical device IP landscape
A cancelled ventilator control patent and a Supreme Court denial together mark a clear shift in risk for this technology domain.
Ventilator control claims face heightened invalidity scrutiny
The successful cancellation of US7802571B2 suggests that ventilator control method patents are viable targets for IPR or other validity challenges. Companies holding or licensing similar patents in this space should audit claim scope against the prior art landscape — particularly for method claims directed to physiological parameter-based ventilator adjustment.
Supreme Court denial removes the last enforcement avenue for this patent
With no appellate path remaining, any party previously threatened with infringement of US7802571B2 can operate freely in that claim space. Design-around investments made in anticipation of enforcement are no longer necessary. Legal teams should update FTO opinions that previously flagged this patent as a risk.
Fleur v Hamilton — key questions answered
Fleur Tehrani petitioned the U.S. Supreme Court to review an invalidity ruling against US7802571B2, a ventilator control method patent. The Supreme Court denied the petition on 20 February 2024, leaving the patent cancelled and unenforceable.
A finding of unpatentability means the patent’s claims were determined not to meet the legal requirements for patentability — likely anticipation or obviousness — in a prior administrative or judicial proceeding. The patent is cancelled and cannot be enforced against any party. The Supreme Court’s denial of certiorari leaves that finding final.
No. A denial of certiorari is not a ruling on the merits. It means the Court declined to review the case, which it does with over 97% of petitions. The practical effect is that the lower tribunal’s unpatentability finding stands, but the Supreme Court has not endorsed or evaluated the reasoning behind it.
No. With the petition denied and the unpatentability determination final, US7802571B2 is cancelled. Tehrani cannot assert the patent in new infringement actions or continue any pending enforcement. The claims are extinguished, and there is no further appellate path available.
The public record for case 23-575 does not identify related continuation or divisional applications. However, the original application number US10/935446 may have spawned related filings. Parties seeking a complete picture of residual IP risk should search the patent family in PatSnap Eureka to identify any co-pending applications with overlapping claim scope.
PatSnap Eureka searches patents and litigation data to answer instantly.